# Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women

## Metadata
**Authors:** Bani Tamraz, Yong Huang, Audrey L French, Seble Kassaye, Kathryn Anastos, Marek J Nowicki, Stephen Gange, Deborah R Gustafson, Peter Bacchetti, Ruth M Greenblatt, Pirro G Hysi, Bradley E Aouizerat, Women’s Interagency HIV Study
**Journal:** Clinical pharmacology and therapeutics
**Date:** 2019 Sep 28
**DOI:** [10.1002/cpt.1605](https://doi.org/10.1002/cpt.1605)
**PMID:** 31562781
**PMCID:** PMC10810687
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10810687/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC10810687/pdf/nihms-1947778.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC10810687/pdf/nihms-1947778.pdf)

## Abstract

SORCS2 rs73208473 was recently associated with decreased atazanavir (ATV) concentration in the hair of women with seropositive HIV. Herein, we report on a pharmacogenetic study of women with seropositive HIV demonstrating a similar association between rs73208473 and dose-adjusted plasma ATV concentration in African Americans.

## FUNDING

University of California San Francisco (UCSF) -Gladstone Center For AIDS Research Grant: Bani Tamraz P30 A1027763; National Institute of Allergy and Infectious Diseases (NIAID): Kathryn Anastos U01-AI-035004; NIAID: Deborah R. Gustafson U01-AI-031834; NIAID: Audrey L. French U01-AI-034993; NIAID: Seble Kassaye U01-AI-034994; NIAID: Ruth M. Greenblatt, Bradley E. Aouizerat U01-AI-034989; NIAID: Stephen J. Gange U01-AI-042590; National Institute of Child Health and Human Development (NICHD): Marek J. Nowicki U01-HD-032632; and UCSF Clinical and Translational Science Institute: Peter Bacchetti UL1-TR000004.

## Footnotes

## References

1. Tamraz B et al. A genome-wide association study identifies a candidate gene associated with atazanavir exposure measured in hair. Clin. Pharmacol. Ther. 104, 949–956 (2018).  [DOI](https://doi.org/10.1002/cpt.1014) | [PMC free article](/articles/PMC6037621/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/29315502/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin.%20Pharmacol.%20Ther&title=A%20genome-wide%20association%20study%20identifies%20a%20candidate%20gene%20associated%20with%20atazanavir%20exposure%20measured%20in%20hair&author=B%20Tamraz&volume=104&publication_year=2018&pages=949-956&pmid=29315502&doi=10.1002/cpt.1014&)

2. Bonora S et al. Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). J. Antimicrob. Chemother. 70, 3696–3699 (2015).  [DOI](https://doi.org/10.1093/jac/dkv208) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/26174719/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Antimicrob.%20Chemother&title=Successful%20pharmacogenetics-based%20optimization%20of%20unboosted%20atazanavir%20plasma%20exposure%20in%20HIV-positive%20patients:%20a%20randomized,%20controlled,%20pilot%20study%20(the%20REYAGEN%20study)&author=S%20Bonora&volume=70&publication_year=2015&pages=3696-3699&pmid=26174719&doi=10.1093/jac/dkv208&)

3. D’Avolio A et al. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J. Antimicrob. Chemother. 69, 3061–3066 (2014).  [DOI](https://doi.org/10.1093/jac/dku234) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/24997317/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Antimicrob.%20Chemother&title=Intracellular%20accumulation%20of%20atazanavir/ritonavir%20according%20to%20plasma%20concentrations%20and%20OATP1B1,%20ABCB1%20and%20PXR%20genetic%20polymorphisms&author=A%20D%E2%80%99Avolio&volume=69&publication_year=2014&pages=3061-3066&pmid=24997317&doi=10.1093/jac/dku234&)

4. Rodriguez-Novoa S et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21, 41–46 (2007).  [DOI](https://doi.org/10.1097/QAD.0b013e328011d7c1) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/17148966/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=AIDS&title=Genetic%20factors%20influencing%20atazanavir%20plasma%20concentrations%20and%20the%20risk%20of%20severe%20hyperbilirubinemia&author=S%20Rodriguez-Novoa&volume=21&publication_year=2007&pages=41-46&pmid=17148966&doi=10.1097/QAD.0b013e328011d7c1&)

5. Siccardi M et al. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C–>T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis. 47, 1222–1225 (2008).  [DOI](https://doi.org/10.1086/592304) | [PMC free article](/articles/PMC3672984/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/18831695/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin.%20Infect.%20Dis&title=Association%20of%20a%20single-nucleotide%20polymorphism%20in%20the%20pregnane%20X%20receptor%20(PXR%2063396C%E2%80%93>T)%20with%20reduced%20concentrations%20of%20unboosted%20atazanavir&author=M%20Siccardi&volume=47&publication_year=2008&pages=1222-1225&pmid=18831695&doi=10.1086/592304&)

6. Schipani A et al. Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob. Agents Chemother. 54, 5242–5250 (2010).  [DOI](https://doi.org/10.1128/AAC.00781-10) | [PMC free article](/articles/PMC2981241/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/20921307/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Antimicrob.%20Agents%20Chemother&title=Population%20pharmacokinetic%20modeling%20of%20the%20association%20between%2063396C->T%20pregnane%20X%20receptor%20polymorphism%20and%20unboosted%20atazanavir%20clearance&author=A%20Schipani&volume=54&publication_year=2010&pages=5242-5250&pmid=20921307&doi=10.1128/AAC.00781-10&)

7. Savic RM et al. Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients. Clin. Pharmacol. Ther. 92, 575–583 (2012).  [DOI](https://doi.org/10.1038/clpt.2012.137) | [PMC free article](/articles/PMC3939416/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/23033116/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Clin.%20Pharmacol.%20Ther&title=Effect%20of%20adherence%20as%20measured%20by%20MEMS,%20ritonavir%20boosting,%20and%20CYP3A5%20genotype%20on%20atazanavir%20pharmacokinetics%20in%20treatment-naive%20HIV-infected%20patients&author=RM%20Savic&volume=92&publication_year=2012&pages=575-583&pmid=23033116&doi=10.1038/clpt.2012.137&)

8. Anderson PL et al. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J. Antimicrob. Chemother. 64, 1071–1079 (2009).  [DOI](https://doi.org/10.1093/jac/dkp317) | [PMC free article](/articles/PMC2760462/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/19710077/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Antimicrob.%20Chemother&title=Atazanavir%20pharmacokinetics%20in%20genetically%20determined%20CYP3A5%20expressors%20versus%20non-expressors&author=PL%20Anderson&volume=64&publication_year=2009&pages=1071-1079&pmid=19710077&doi=10.1093/jac/dkp317&)

9. Gandhi M et al. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J. Infect. Dis. 206, 1453–1461 (2012).  [DOI](https://doi.org/10.1093/infdis/jis508) | [PMC free article](/articles/PMC3466997/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/22927450/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=J.%20Infect.%20Dis&title=A%20single-nucleotide%20polymorphism%20in%20CYP2B6%20leads%20to%20>3-fold%20increases%20in%20efavirenz%20concentrations%20in%20plasma%20and%20hair%20among%20HIV-infected%20women&author=M%20Gandhi&volume=206&publication_year=2012&pages=1453-1461&pmid=22927450&doi=10.1093/infdis/jis508&)

10. Abdelkawy KS, Donia AM, Turner RB & Elbarbry F Effects of lemon and Seville orange juices on the pharmacokinetic properties of Sildenafil in healthy subjects. Drugs R. D. 16, 271–278 (2016).  [DOI](https://doi.org/10.1007/s40268-016-0140-1) | [PMC free article](/articles/PMC5045831/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/27550653/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Drugs%20R.%20D&title=Effects%20of%20lemon%20and%20Seville%20orange%20juices%20on%20the%20pharmacokinetic%20properties%20of%20Sildenafil%20in%20healthy%20subjects&author=KS%20Abdelkawy&author=AM%20Donia&author=RB%20Turner&author=F%20Elbarbry&volume=16&publication_year=2016&pages=271-278&pmid=27550653&doi=10.1007/s40268-016-0140-1&)
